Zobrazeno 1 - 10
of 981
pro vyhledávání: '"Mark R, Litzow"'
Autor:
Neil D. Palmisiano, Ju‐Whei Lee, David F. Claxton, Elisabeth M. Paietta, Hassan Alkhateeb, Jae Park, Nikolai A. Podoltsev, Ehab L. Atallah, Dale G. Schaar, Shira N. Dinner, Jonathan A. Webster, Selina M. Luger, Mark R. Litzow
Publikováno v:
eJHaem, Vol 5, Iss 5, Pp 951-956 (2024)
Abstract Introduction Relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) remains a therapeutic challenge. Preclinical data in both B‐ and T‐ALL suggests synergy of venetoclax (VEN) with vincristine (VCR
Externí odkaz:
https://doaj.org/article/c91b8c18158941c486ff17cf61cf66fd
Autor:
Mark R. Litzow
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/d3cb12e9075b43f389665d3f6ac40dfd
Autor:
Kashi Raj Bhattarai, Robert J. Mobley, Kelly R. Barnett, Daniel C. Ferguson, Baranda S. Hansen, Jonathan D. Diedrich, Brennan P. Bergeron, Satoshi Yoshimura, Wenjian Yang, Kristine R. Crews, Christopher S. Manring, Elias Jabbour, Elisabeth Paietta, Mark R. Litzow, Steven M. Kornblau, Wendy Stock, Hiroto Inaba, Sima Jeha, Ching-Hon Pui, Cheng Cheng, Shondra M. Pruett-Miller, Mary V. Relling, Jun J. Yang, William E. Evans, Daniel Savic
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Defining genetic factors impacting chemotherapy failure can help to better predict response and identify drug resistance mechanisms. However, there is limited understanding of the contribution of inherited noncoding genetic variation on inte
Externí odkaz:
https://doaj.org/article/50de02b6348449e7a1264f8dc70d8016
Autor:
Ayalew Tefferi, Animesh Pardanani, Kebede H. Begna, Aref Al-Kali, William J. Hogan, Mark R. Litzow, Rhett P. Ketterling, Kaaren K. Reichard, Naseema Gangat
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/f92ca6110c604f30a18b2d513517e4cc
Autor:
Clifford M. Csizmar, Antoine N. Saliba, Patricia T. Greipp, Hassan Alkhateeb, Kebede H. Begna, James M. Foran, Naseema Gangat, William J. Hogan, C. Christopher Hook, Mark R. Litzow, Abhishek A. Mangaonkar, Jeanne M. Palmer, Animesh Pardanani, Mithun V. Shah, Ayalew Tefferi, Mehrdad Hefazi Torghabeh, Alexandra P. Wolanskyj-Spinner, Mrinal M. Patnaik, Scott H Kaufmann, Aref Al-Kali
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/aed91acc184e4fa6b1a7c4380916eac0
Autor:
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M. Shallis, Sacchi de Camargo Correia Guilherme, Aaron D. Goldberg, Antoine N. Saliba, Anand Patel, Jan P. Bewersdorf, Adam S. DuVall, Danielle Bradshaw, Yasmin Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M. Zeidan, Vamsi Kota, Mark R. Litzow
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/768054ee7a0b494192b71e0f348ee872
Autor:
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M. Shallis, Emily C. Craver, Zhuo Li, Aaron D. Goldberg, Antoine N. Saliba, Anand Patel, Jan P. Bewersdorf, Adam Duvall, Madelyn Burkart, Danielle Bradshaw, Yasmin Abaza, Maximilian Stahl, Neil Palmisiano, Guru Subramanian Guru Murthy, Amer M. Zeidan, Vamsi Kota, Mrinal M. Patnaik, Mark R. Litzow
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
While there is clear evidence to suggest poorer outcome associated with multi-hit (MH) TP53 mutation compared to single-hit (SH) in lower-risk myelodysplastic syndrome (MDS), data are conflicting in both higher-risk MDS and acute myeloid leukemia (AM
Externí odkaz:
https://doaj.org/article/c1694d4dbade4d11b7fd3ea5b5113ad5
Autor:
Nickolas Steinauer, Kristen McCullough, Aref Al-Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek A. Mangaonkar, Antoine N. Saliba, Mehrdad Torghabeh, Mark R. Litzow, William J. Hogan, Mithun Shah, Mrinal M. Patnaik, Animesh Pardanani, Talha Badar, Hemant Murthy, James Foran, Cecilia Arana Yi, Ayalew Tefferi, Naseema Gangat
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/267fe382059e4e95888968cd0166caf1
Autor:
Faiqa Farrukh, Maymona Abdelmagid, Abhishek Mangaonkar, Mrinal Patnaik, Aref Al-Kali, Michelle A. Elliott, Kebede H. Begna, Christopher C. Hook, William J. Hogan, Animesh Pardanani, Mark R. Litzow, Rhett P. Ketterling, Naseema Gangat, Daniel A. Arber, Attilio Orazi, Rong He, Kaaren Reichard, Ayalew Tefferi
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
The revised 4th edition of the World Health Organization (WHO4R) classification lists myelodysplastic syndromes with ring sideroblasts (MDS-RS) as a separate entity with single lineage (MDS-RS-SLD) or multilineage (MDS-RS-MLD) dysplasia. The more rec
Externí odkaz:
https://doaj.org/article/79912b1af5524ceab5f595d1fdf3afc5
Autor:
Talha Badar, Yenny A. Moreno Vanegas, Ahmad Nanaa, James M. Foran, Aref Al-Kali, Abhishek Mangaonkar, Hemant Murthy, Hassan B. Alkhateeb, David Viswanatha, Rong He, Mithun Shah, Cecilia Arana Yi, Mark R. Litzow, Naseema Gangat, Ayalew Tefferi, Mrinal M. Patnaik
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-7 (2023)
Abstract We have previously recognized the genotypic and prognostic heterogeneity of U2AF1 mutations (MT) in myelofibrosis (MF) and myelodysplastic syndromes (MDS). In the current study, we considered 179 U2AF1-mutated patients with clonal cytopenia
Externí odkaz:
https://doaj.org/article/9694d5392e3a47e9abd0361375cc8391